Ardelyx (ARDX) said its drug Xphozah lowered serum phosphate levels and improved patient satisfaction in adults with chronic kidney disease on dialysis.

Patients taking Xphozah had an average one milligram per deciliter drop in serum phosphate, with almost half achieving reductions of at least that amount, the company said Friday in a statement.

In a separate survey, 63% of patients reported improved phosphate levels, and 69% said their outlook on phosphate control had improved, the company said.

The findings were based on data presented at the American Society of Nephrology's Kidney Week in Houston.